<SEC-DOCUMENT>0001104659-24-075300.txt : 20240627
<SEC-HEADER>0001104659-24-075300.hdr.sgml : 20240627
<ACCEPTANCE-DATETIME>20240627060225
ACCESSION NUMBER: 0001104659-24-075300
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 15
CONFORMED PERIOD OF REPORT: 20240626
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20240627
DATE AS OF CHANGE: 20240627
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verona Pharma plc
CENTRAL INDEX KEY: 0001657312
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38067
FILM NUMBER: 241075183
BUSINESS ADDRESS:
STREET 1: 3 MORE LONDON RIVERSIDE
CITY: LONDON
STATE: X0
ZIP: SE1 2RE
BUSINESS PHONE: 011-44-0-2032834200
MAIL ADDRESS:
STREET 1: 3 MORE LONDON RIVERSIDE
CITY: LONDON
STATE: X0
ZIP: SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2418370d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:vrna="http://veronapharma.com/20240626">
<head>
<title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_vrna_veronapharma.com_20240626 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240626_20240626 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001657312 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000004" name="dei:EntityCentralIndexKey">0001657312</ix:nonNumeric>
<ix:nonNumeric contextRef="AsOf2024-06-26" id="xdx2ixbrl0012" name="dei:EntityIncorporationStateCountryCode">X0</ix:nonNumeric>
<ix:nonNumeric contextRef="AsOf2024-06-26" id="xdx2ixbrl0018" name="dei:EntityAddressCountry">GB</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="vrna-20240626.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="AsOf2024-06-26">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-06-26</xbrli:startDate>
<xbrli:endDate>2024-06-26</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USDPShares">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
</ix:resources>
</ix:header>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>UNITED STATES</b></span></p>
<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20240626__20240626_zH3t4iKmBRHk"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of report (Date of earliest event reported): <span id="xdx_901_edei--DocumentPeriodEndDate_c20240626__20240626_zQerYy5uAucg"><ix:nonNumeric contextRef="AsOf2024-06-26" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 26, 2024</ix:nonNumeric></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_905_edei--EntityRegistrantName_c20240626__20240626_zGL0RhZF0j1d"><b><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000011" name="dei:EntityRegistrantName">Verona
Pharma plc</ix:nonNumeric></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_dxL_c20240626__20240626_zFxWrIeLrYDf" title="::XDX::X0" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl0012">United
Kingdom</span></b></span></td>
<td style="vertical-align: bottom; font-size: 10pt"> </td>
<td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_906_edei--EntityFileNumber_c20240626__20240626_zr8I6DkzD5J" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000013" name="dei:EntityFileNumber">001-38067</ix:nonNumeric></b></span></td>
<td style="vertical-align: bottom; font-size: 10pt"> </td>
<td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20240626__20240626_zQPLnHUax6ze" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-1489389</ix:nonNumeric></b></span></td></tr>
<tr>
<td style="vertical-align: top; width: 33%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State
or other jurisdiction</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)</b></p></td>
<td style="vertical-align: bottom; width: 1%; font-size: 10pt"> </td>
<td style="vertical-align: top; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p></td>
<td style="vertical-align: bottom; width: 1%; font-size: 10pt"> </td>
<td style="vertical-align: top; width: 33%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS
Employer</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20240626__20240626_zTOMX4zrAqL4"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000015" name="dei:EntityAddressAddressLine1">One
Central Square</ix:nonNumeric></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20240626__20240626_zKeL32RwwX1g"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000016" name="dei:EntityAddressCityOrTown">Cardiff</ix:nonNumeric>
</span></b><b><span id="xdx_904_edei--EntityAddressPostalZipCode_c20240626__20240626_z52pAMcug3sh"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000017" name="dei:EntityAddressPostalZipCode">CF10 1FS</ix:nonNumeric></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressCountry_dxL_c20240626__20240626_zVaT3ISDzr9f" title="::XDX::GB"><span style="-sec-ix-hidden: xdx2ixbrl0018">United Kingdom</span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices) (Zip
Code)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>+<span id="xdx_90F_edei--CountryRegion_c20240626__20240626_zvCIvrJOF8H9"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000019" name="dei:CountryRegion">44</ix:nonNumeric>
</span></b><b><span id="xdx_90D_edei--CityAreaCode_c20240626__20240626_z3eeLXN9gB1j"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000020" name="dei:CityAreaCode">203</ix:nonNumeric></span></b><b> <span id="xdx_904_edei--LocalPhoneNumber_c20240626__20240626_zTrLITAH1Rwe"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000021" name="dei:LocalPhoneNumber">283
4200</ix:nonNumeric></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant’s telephone number, including
area code)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 4%"> </td>
<td style="vertical-align: top; width: 4%"><span id="xdx_90B_edei--WrittenCommunications_c20240626__20240626_z7T9hT2sGJr7" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-06-26" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">¨</ix:nonNumeric></span></td>
<td style="vertical-align: top; width: 92%"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425) </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 4%"> </td>
<td style="vertical-align: top; width: 4%"><span id="xdx_90F_edei--SolicitingMaterial_c20240626__20240626_zLVom3oUyM3b" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-06-26" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">¨</ix:nonNumeric></span></td>
<td style="vertical-align: top; width: 92%"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 4%"> </td>
<td style="vertical-align: top; width: 4%"><span id="xdx_903_edei--PreCommencementTenderOffer_c20240626__20240626_zqM1DCPRvpoa" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-06-26" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">¨</ix:nonNumeric></span></td>
<td style="vertical-align: top; width: 92%"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 4%"> </td>
<td style="vertical-align: top; width: 4%"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20240626__20240626_zs12Z7YIJuXg" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-06-26" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">¨</ix:nonNumeric></span></td>
<td style="vertical-align: top; width: 92%"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(b) of
the Act: </b></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border: black 1pt solid; width: 37%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Title
of each class</span></td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Trading
Symbol(s)</span></td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Name
of each exchange on which <br/>
registered</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_906_edei--Security12bTitle_c20240626__20240626_zaWh5ju4jztj" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000026" name="dei:Security12bTitle">Ordinary
shares, nominal value £0.05 per share*</ix:nonNumeric></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_90A_edei--TradingSymbol_c20240626__20240626_zhDEDUwotJ9k" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-06-26" id="Fact000027" name="dei:TradingSymbol">VRNA</ix:nonNumeric></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_90E_edei--SecurityExchangeName_c20240626__20240626_zqZzRVklp3gj" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-06-26" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
Nasdaq Stock Market LLC</ix:nonNumeric></span> <br/>
(Nasdaq Global Market)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>* The ordinary shares are represented by American
Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section 12(a) of the Securities
Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20240626__20240626_z0P6J5TPXbxk" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-06-26" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">¨</ix:nonNumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">¨</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"> </span></p>
<!-- Field: Page; Sequence: 1 -->
<div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 7.01.</b></td><td><b>Regulation FD Disclosure</b></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 26, 2024, Verona Pharma
plc (the “Company”) issued a press release announcing the U.S. Food and Drug Administration’s (“FDA”) approval
of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. A copy of
the press release is attached as Exhibit 99.1 and incorporated herein by reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information contained
under Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act except as may be expressly set forth by specific reference in such filing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 8.01.</b></td><td><b>Other Events.</b></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 26, 2024, the Company
announced that the FDA had approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD)
in adult patients.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ohtuvayre is a first-in-class
selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 that combines bronchodilator and non-steroidal anti-inflammatory
effects in one molecule. Ohtuvayre is delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory
flow rates or complex hand-breath coordination.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects Ohtuvayre
to be available in the third quarter of 2024 through an exclusive network of accredited specialty pharmacies. Complete prescribing information
is available at https://ohtuvayrehcp.com/files/Ohtuvayre-US-Prescribing-Information.pdf.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 1in"><span style="font-size: 10pt"><b>Item 9.01</b></span></td>
<td><span style="font-size: 10pt"><b>Financial Statements and Exhibits. </b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">(d) Exhibits</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
<td> </td>
<td style="white-space: nowrap"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
<tr>
<td> </td>
<td colspan="2"> </td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top"><a href="tm2418370d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">99.1*</span></a></td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: top"><a href="tm2418370d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Press Release, dated June 26, 2024.</span></a></td></tr>
<tr>
<td> </td>
<td colspan="2"> </td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">104</span></td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL document).</span></td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top"> </td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: top"> </td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">*</span></td>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: top"><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K (this “Form 8-K”) contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this
press release other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,”
“believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,”
“possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements
include, but are not limited to, statements regarding the anticipated timing of commercial availability and our ability to successfully
market and sell Ohtuvayre.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<!-- Field: Page; Sequence: 2 -->
<div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are based on management's
current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause the Company’s actual results, performance or achievements to be materially different
from the Company’s expectations expressed or implied by the forward-looking statements, including, but not limited to, the
following: the Company’s limited operating history; the Company’s need for additional funding to complete development
and commercialization of Ohtuvayre which may not be available and which may force the Company to delay, reduce or eliminate its
development or commercialization efforts; the Company’s reliance on the success of Ohtuvayre, its only commercial product; the
Company’s reliance on third-party manufacturers and suppliers; the efficacy of Ohtuvayre compared to competing drugs; the
Company’s ability to successfully commercialize Ohtuvayre; serious adverse, undesirable or unacceptable side effects
associated with Ohtuvayre which could adversely affect the Company’s ability to commercialize Ohtuvayre; failure to develop
Ohtuvayre for additional indications, alternate delivery methods, or as a combination therapy; failure to obtain approval for and
commercialize Ohtuvayre in multiple major pharmaceutical markets; lawsuits related to patents covering Ohtuvayre and the potential
for the Company’s patents to be found invalid or unenforceable; lawsuits related to the Company’s licensing of patents
and know-how from third parties for the commercialization of Ohtuvayre; changes in the Company’s tax rates, unavailability of
certain tax credits or reliefs or exposure to additional tax liabilities or assessments that could affect the Company’s
profitability, and audits by tax authorities that could result in additional tax payments for prior periods; and the Company’s
vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics
or pandemics. These and other important factors discussed under the caption “Risk Factors” in the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2024 filed with the Securities and Exchange Commission
(“SEC”) on May 10, 2024, and the Company’s other reports filed with the SEC, could cause actual results to differ
materially from those indicated by the forward-looking statements made in this Form 8-K. Any such forward-looking statements
represent management's estimates as of the date of this Form 8-K. While the Company may elect to update such forward-looking
statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause the
Company’s views to change, except as required under applicable law. These forward-looking statements should not be relied upon
as representing the Company’s views as of any date subsequent to the date of this Form 8-K.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<!-- Field: Page; Sequence: 3 -->
<div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>SIGNATURES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td> </td>
<td colspan="2"><span style="font-size: 10pt"><b>VERONA PHARMA PLC</b></span></td></tr>
<tr>
<td style="width: 50%"> </td>
<td style="width: 5%"> </td>
<td style="width: 45%"> </td></tr>
<tr>
<td><span style="font-size: 10pt">Date: June 27, 2024</span></td>
<td><span style="font-size: 10pt">By:</span></td>
<td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"> /s/ David Zaccardelli, Pharm. D.</span></td></tr>
<tr>
<td> </td>
<td><span style="font-size: 10pt">Name:</span></td>
<td><span style="font-size: 10pt"> David Zaccardelli, Pharm. D.</span></td></tr>
<tr>
<td> </td>
<td><span style="font-size: 10pt">Title:</span></td>
<td><span style="font-size: 10pt"> President and Chief Executive Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<!-- Field: Page; Sequence: 4; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WcoW68HHpCKyEInoddEplnRHZjfTT+ov25RouDAM9565QoRiR1tdI8N1XWRwxqatlUMo8IaMpkSfSPeHBPwu8K6tY2XceP7AlDyDnlnOpCy9MUY7bbFKIFrNpVcM0TKJY8iPIvj6KZmbrtA4rWpQpoKcqWWNTvEwfTirngw1w1h1QbaaTAKLWTTZb5DRQsKJOvUifljIslQE4TiB2DE9W5/a9A7Nl4RNjY2vsxP9V/ABC9VKlQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2418370d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="text-align: right; margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B> </FONT></P>
<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="text-align: right; margin: 0; font-size: 10pt"><IMG SRC="tm2418370d1_ex99-1img001.jpg" ALT=""><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Verona Pharma
Announces US FDA Approval of Ohtuvayre<SUP>TM</SUP> (ensifentrine) </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>Ohtuvayre is
indicated for the maintenance treatment of COPD allowing for broad use in COPD patients</I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>First inhaled
COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects </I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>Conference call
tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST</I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LONDON and RALEIGH,
N.C., June 26, 2024</B> – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces
the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive
pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the
maintenance treatment of COPD in more than 20 years.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Ohtuvayre is a
first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 (“PDE3 and PDE4”) that
combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is delivered directly to the lungs through
a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">“The approval
of Ohtuvayre is a significant advance in COPD care, and we believe Ohtuvayre’s novel profile can change the treatment paradigm
for COPD,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma. “We plan to launch
Ohtuvayre in the third quarter 2024, ensuring Ohtuvayre is available to help the millions of patients who still experience daily COPD
symptoms.”</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Michael Wells,
MD, Associate Professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Alabama Birmingham, commented:
“In my experience, despite maintenance therapy, most patients report grappling with daily symptoms, including breathlessness and
persistent coughing. COPD has a significant impact on both mortality and morbidity in the US, and until today, innovation in inhaled
treatment modalities has been limited to combinations of existing treatment classes for over two decades. Ohtuvayre, as a first-in-class
PDE3 and PDE4 inhibitor, offers a needed, unique approach and is an important advance in the treatment of COPD.”</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The US approval
of Ohtuvayre was based on extensive data including the Phase 3 ENHANCE trials, the results of which were published in the <I><U>American
Journal of Respiratory and Critical Care Medicine</U></I>. In the ENHANCE trials, Ohtuvayre demonstrated clinical benefits both alone
and when used with other maintenance therapies. Ohtuvayre was well-tolerated in a broad population of subjects with moderate to severe
COPD.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company is
fully staffed to launch and expects Ohtuvayre to be available in the third quarter 2024 through an exclusive network of accredited specialty
pharmacies.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<!-- Field: Page; Sequence: 1 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>
<DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Conference Call
</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Verona Pharma will
host an investment community conference call at 8:30 a.m. EDT / 1:30 p.m. BST on Thursday, June 27, 2024 to discuss the US approval of
Ohtuvayre. To participate, please dial one of the following numbers and ask to join the Verona Pharma call:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">·</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">+1-833-816-1396 for callers in
the United States</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">·</FONT></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">+1-412-317-0489
for international callers</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">A live webcast
will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the
audio replay will be available for 90 days.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About Ohtuvayre
(ensifentrine)</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Ohtuvayre is the
first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities
in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled
Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating
statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate,
a LAMA, is currently under development for the maintenance treatment of COPD. Ensifentrine has potential applications for development
in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Important Safety
Information</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Indication </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Ohtuvayre is a prescription medicine
used to treat COPD in adults. COPD is a chronic (long-term) lung disease that includes chronic bronchitis, emphysema, or both.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>What is the most important information
I should know about Ohtuvayre?</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Ohtuvayre can cause serious side effects,
including:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">·</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sudden
breathing problems immediately after inhaling your medicine. If you have sudden breathing
problems immediately after inhaling your medicine, stop using Ohtuvayre and call your healthcare
provider right away or go to the nearest hospital emergency room right away. </FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">·</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mental
health problems including suicidal thoughts and behavior. You may experience mood or behavior
changes when taking Ohtuvayre. Call your healthcare provider right away if you have any of
these symptoms, especially if they are new, worse, or worry you: thoughts of suicide or dying,
attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety, new or worse
depression, acting on dangerous impulses, and/or other unusual changes in your behavior or
mood.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Do not use Ohtuvayre
to treat sudden breathing problems. Always have a rescue inhaler with you.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Who Should Not use Ohtuvayre?</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Do not use Ohtuvayre if you have had
an allergic reaction to ensifentrine or any of the ingredients in Ohtuvayre.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>What should I tell my healthcare
provider before using Ohtuvayre?</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Before you use
Ohtuvayre, tell your healthcare professional if you have or have had a history of mental health problems including depression and suicidal
behavior; have liver problems; are pregnant or plan to become pregnant; are breastfeeding. It is not known if Ohtuvayre may harm your
unborn baby. It is not known if the medicine in Ohtuvayre passes into your breast milk and if it can harm your baby.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tell your healthcare
provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<!-- Field: Page; Sequence: 2 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>
<DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>What are the
most common side effects of Ohtuvayre?</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The most common
side effects of Ohtuvayre include back pain, high blood pressure, bladder infection and diarrhea.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">These are not all
the possible side effects of Ohtuvayre. Call your doctor for medical advice about side effects. You may report side effects to FDA at
1-800-FDA-1088.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>This summary
does not include all the information about Ohtuvayre and is not meant to take the place of a discussion with your healthcare provider
about your treatment.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>For further
information, please see the <U>full Prescribing Information</U>, including the Patient Information Leaflet.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>You are encouraged
to report negative side effects of prescription drugs to the FDA. Visit <U>www.fda.gov/medwatch</U> or call <U>1-800-FDA-1088</U>.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About COPD</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Chronic obstructive
pulmonary disease (“COPD”) refers to a group of diseases that cause airflow blockage and breathing-related problems, such
as emphysema and chronic bronchitis. More than 390 million people worldwide are living with COPD, and more than 8.6 million Americans
are treated chronically<SUP>1-2</SUP>. Symptoms include increased shortness of breath, frequent coughing (with and without mucus), wheezing,
tightness in the chest and unusual tiredness. Approximately 50% of COPD patients experience almost daily symptoms<SUP>3</SUP>. There
is no cure for COPD and despite available treatment options, it is the third leading cause of death globally.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>Adeloye
D, et al. <I>Lancet Respir Med.</I> 2022;10(5):447-458</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>2</SUP>Verona
IQVIA Ensifentrine Market Research</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>3</SUP>Phreesia
2022 COPD Patient Survey</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About Verona
Pharma</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Verona Pharma is
a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases
with significant unmet medical needs, including COPD, non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory
diseases. For more information, please visit www.veronapharma.com.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">For further information
please contact:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="border: Black 1pt solid; padding: 3.75pt 7.5pt; font-size: 10pt; width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Verona
Pharma plc</B></FONT></TD>
<TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3.75pt 7.5pt 3pt; font-size: 10pt; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
+1-844-341-9901</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3.75pt 7.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victoria
Stewart, Senior Director of Investor Relations and Communications</FONT></TD>
<TD STYLE="border-right: Black 1pt solid; font-size: 10pt; border-bottom: Black 1pt solid; padding: 3.75pt 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>IR@veronapharma.com</U></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3.75pt 7.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Argot
Partners</B><BR>
US Investor Enquiries</FONT></TD>
<TD STYLE="border-right: Black 1pt solid; font-size: 10pt; border-bottom: Black 1pt solid; padding: 3.75pt 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
+1-212-600-1902<BR>
<U>verona@argotpartners.com</U></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3.75pt 7.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ten
Bridge Communications</B><BR>
International / US Media Enquiries</FONT></TD>
<TD STYLE="border-right: Black 1pt solid; font-size: 10pt; border-bottom: Black 1pt solid; padding: 3.75pt 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
+1-774-278-8273<BR>
<U>tbcverona@tenbridgecommunications.com</U></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3.75pt 7.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nichole
Bobbyn</FONT></TD>
<TD STYLE="border-right: Black 1pt solid; font-size: 10pt; border-bottom: Black 1pt solid; padding: 3.75pt 7.5pt"><FONT STYLE="font-size: 10pt"> </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B> </B></FONT></P>
<!-- Field: Page; Sequence: 3 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>
<DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Forward-Looking Statements</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This press
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release other than statements of historical fact should be considered forward-looking statements.
Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,”
“may,” “potential,” “prepare,” “possible” and similar words and expressions are
intended to identify forward-looking </FONT>statements. These forward-looking statements include, but are not limited to, statements
regarding the potential benefits, efficacy, and approval of our drug Ohtuvayre, including, but not limited to, statements relating
to the <FONT STYLE="font-family: Times New Roman, Times, Serif">potential to change the treatment paradigm for COPD patients, the
anticipated timing of commercial availability and our ability to successfully market and sell Ohtuvayre.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">These forward-looking
statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and
unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following:
our limited operating history; our need for additional funding to complete development and commercialization of Ohtuvayre which may not
be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; our reliance on the success
of Ohtuvayre, our only commercial product; our reliance on third-party manufacturers and suppliers; the efficacy of Ohtuvayre compared
to competing drugs; our ability to successfully commercialize Ohtuvayre; serious adverse, undesirable or unacceptable side effects associated
with Ohtuvayre which could adversely affect our ability to commercialize Ohtuvayre; failure to develop Ohtuvayre for additional indications,
alternate delivery methods, or as a combination therapy; failure to obtain approval for and commercialize Ohtuvayre in multiple major
pharmaceutical markets; lawsuits related to patents covering Ohtuvayre and the potential for our patents to be found invalid or unenforceable;
lawsuits related to our licensing of patents and know-how from third parties for the commercialization of Ohtuvayre; changes in our tax
rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments that could affect our
profitability, and audits by tax authorities that could result in additional tax payments for prior periods; and our vulnerability to
natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics. These
and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period
ended March 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on May 10, 2024, and our other reports filed
with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events
cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing
our views as of any date subsequent to the date of this press release.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"> </FONT></P>
<!-- Field: Page; Sequence: 4; Options: Last -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT> </P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2418370d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2418370d1_ex99-1img001.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P 1" !\ 0,# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL
MOQ'+=P>'-0GL&*W4,+2Q8 .2OS;>?7&/QH U,TF15:QOK?4-.M[ZW<-;SQK*
MC'CY2,BJ'B*\GM;:SAM)/+N+N]A@5@ <*6W/U_V%>BSO8+FSG-)D4"L%+Z^N
M?&LMG#(HTZTLU:<;1EII&^49Z\*I/_ A0D!KB]MS?FR$G^D"+S=FT_<SC.>G
M6K%<WX7M[V:?4-9U.W:"[O)BD<3=8K="1&OL3EF/NU=)3>CL)!1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C#*$
MX)'4=J"0 23@"HXYHIXO,AD5T/1E.0?RH P-.UFXL-530M:8-=2 M:W@7:ET
MH['' D ZCH>HZX")KEY!XK?1=2M(Q;W +V=S'G:XQGRV!_CPLA], 5#K>H6<
M@FT_Q%836MFS_N;Y6W1#!^5]XYB8'') /0FL>^NM0;3%TC6,K<!@VG:XA!A
MDF!S"6Q]QCC!'0]C\P%:)7(N5=2C%A\,]9T=2<:7?+;INZ[#-'(G_CCJ/PKI
M;NY2]\?65D/N:9:/>2,>@>3]V@_[Y\P_B*X3Q%K#7FD:RTT/V:YN[:W^TVY_
MY97,%PB2#\5>(CUS&R:QJ>IVML^;G6+UDG=#S'80?NV^FYE=1ZER>U:..
ME_ZZ$W.P\.:Q+KMG-J'D>5922E;3=G=)&.-Y]B<D>V/6I]+T^.SN-2N%G\Z2
M\N?-D;CY<*J!?P"#]:S-<O[J,Q:#X?$2ZE)&#O(^2TAZ;V'KQA1W/L#6QI6F
M6^CZ?%9VRGRT&2S'+.QY+,>Y)))/O6#-"]147GQ>=Y/F)YNW=LW#=CUQZ5+2
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5;J%WCS_ B0$'\F&1]!5QUT/9RY>WI5,)U>J]4:-@1XJ^,-Q?'Y[*QD,F[L
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M3;RU2:T10J(W\.!@$'J#[USUG\+_ O:&4_9))_,!7]](3M!&,#&,?7K[UVE
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$@#__V0$!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>vrna-20240626.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
<!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
<!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayPybOdzZR+qYkxtmB6bQlqrykuJ0qu7yHyG32GEcML -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:vrna="http://veronapharma.com/20240626" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20240626">
<annotation>
<appinfo>
<link:roleType roleURI="http://veronapharma.com/role/Cover" id="Cover">
<link:definition>00000001 - Document - Cover</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="vrna-20240626_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
<link:linkbaseRef xlink:type="simple" xlink:href="vrna-20240626_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>vrna-20240626_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
<!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
<!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>vrna-20240626_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
<!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
<!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:href="vrna-20240626.xsd#Cover" xlink:type="simple" />
<link:presentationLink xlink:type="extended" xlink:role="http://veronapharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
<link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
<link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
<link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
<link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
<link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
<link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
<link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
<link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
<link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
<link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
<link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
<link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
<link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
<link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
<link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
<link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
<link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
<link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
<link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
<link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
<link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
<link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
<link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
<link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
<link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
<link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
<link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
<link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
<link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
<link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
<link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
<link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
<link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
<link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
<link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
<link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
<link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
<link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
<link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
<link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
<link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
<link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
<link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
<link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
<link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
<link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
<link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
<link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
<link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
<link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
<link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
<link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
<link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
<link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
<link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
<link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
<link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139639131723696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 26, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona
Pharma plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One
Central Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cardiff<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">CF10 1FS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283
4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
shares, nominal value £0.05 per share*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0 ( $PPVU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M " !,,-M89"9+W>\ K @ $0 &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.LW00%'7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0:@\8^TG/L T5VE*Y&WW9)8]B( W/0 D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGD!)N09/;*QA Q.P" M1-+5%C9$,]_&$M[C@PV=L9YA%H)8\=9R@*BL0S30Q
M',>VA@M@@C%%G[X+9!?B7/T3.W= G))C<DMJ&(9R6,VYO$,%;T^/+_.ZA>L2
MFPXI_TI.\S'01IPGOZ[N[K</HE%271=R7:B;;26U5+JZ?9]<?_A=A'UOW<[]
M8^.S8%/#K[MHO@!02P,$% @ 3##;6)E<G",0!@ G"< !, !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>	+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !,,-M8O@ # & $ ($0 & 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
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MIA[@#OR.[,Z8',@: 7'91L"]73QNOD_"PL9+Q80&/RU^)G,>YE!OM8;9H/0
M+B[AF'A"X,_ MH>#W4D%)R!XH5Y8DG/B-O?M#_ZYWR49C+[H] LVC,KW ]RM
MGS2+7#G.W]*%JBW&!H'GQ_LQ1E(9?H#;\RZ#Y/8U7#&YY ?WCPU"]^/YS?AW
MC*ER^0 WZ>TB=)MRO719^@@*=N4<)6.R?JYQP8/UU]H[U[K?"+XP]T1#$AZ#
MD']^ ;IZ<^S>-*S*BJ/N0EDX.!>7*\[@W7 =X/M8*;MKN--S^>/'Z%]02P,$
M% @ 3##;6)^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP
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M>RHY_U=3_ 102P,$% @ 3##;6)>*NQS $P( L !?<F5L<R\N
M<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9
M>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:
M+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU
M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*
MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04 " !,,-M8JL0B%C,! B @ #P
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MLN48<?R>Y0]02P,$% @ 3##;6"0>FZ*M ^ $ !H !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C
M$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C
M,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI
M160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%
MKLWC":[?#'!X=/X!4$L#!!0 ( $PPVUAED'F2&0$ ,\# 3 6T-O
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MS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#% @ 3##;6 =!
M36*! L0 ! ( ! &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4 " !,,-M89"9+W>\ K @ $0 @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " !,,-M8F5R<(Q & "<)P
M$P @ '- 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M ( $PPVUB^ , 8 0 @1 8 " @0X( !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4 " !,,-M8GZ ;\+$" #B#
M#0 @ &D# >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0 ( $PP
MVUB7BKL<P !," + " 8 / !?<F5L<R\N<F5L<U!+
M 0(4 Q0 ( $PPVUBJQ"(6,P$ "(" / " 6D0 !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !,,-M8)!Z;HJT #X 0 &@
M @ ')$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4 " !,,-M899!YDAD! #/ P $P @ &N$@ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #X$P !
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
<Version>3.24.1.1.u2</Version>
<ProcessingTime/>
<ReportFormat>html</ReportFormat>
<ContextCount>1</ContextCount>
<ElementCount>23</ElementCount>
<EntityCount>1</EntityCount>
<FootnotesReported>false</FootnotesReported>
<SegmentCount>0</SegmentCount>
<ScenarioCount>0</ScenarioCount>
<TuplesReported>false</TuplesReported>
<UnitCount>3</UnitCount>
<MyReports>
<Report instance="tm2418370d1_8k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R1.htm</HtmlFileName>
<LongName>00000001 - Document - Cover</LongName>
<ReportType>Sheet</ReportType>
<Role>http://veronapharma.com/role/Cover</Role>
<ShortName>Cover</ShortName>
<MenuCategory>Cover</MenuCategory>
<Position>1</Position>
</Report>
<Report>
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<LongName>All Reports</LongName>
<ReportType>Book</ReportType>
<ShortName>All Reports</ShortName>
</Report>
</MyReports>
<Logs>
<Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode - tm2418370d1_8k.htm 21</Log>
</Logs>
<InputFiles>
<File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2418370d1_8k.htm">tm2418370d1_8k.htm</File>
<File>vrna-20240626.xsd</File>
<File>vrna-20240626_lab.xml</File>
<File>vrna-20240626_pre.xml</File>
</InputFiles>
<SupplementalFiles/>
<BaseTaxonomies>
<BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase>true</HasPresentationLinkbase>
<HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
"version": "2.2",
"instance": {
"tm2418370d1_8k.htm": {
"nsprefix": "vrna",
"nsuri": "http://veronapharma.com/20240626",
"dts": {
"inline": {
"local": [
"tm2418370d1_8k.htm"
]
},
"schema": {
"local": [
"vrna-20240626.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
"https://xbrl.sec.gov/country/2023/country-2023.xsd",
"https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
]
},
"labelLink": {
"local": [
"vrna-20240626_lab.xml"
]
},
"presentationLink": {
"local": [
"vrna-20240626_pre.xml"
]
}
},
"keyStandard": 23,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 4,
"http://xbrl.sec.gov/dei/2023": 4
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 59,
"unitCount": 3,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2023": 23
},
"report": {
"R1": {
"role": "http://veronapharma.com/role/Cover",
"longName": "00000001 - Document - Cover",
"shortName": "Cover",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "AsOf2024-06-26",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm2418370d1_8k.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "AsOf2024-06-26",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm2418370d1_8k.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AmendmentDescription",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Description",
"documentation": "Description of changes contained within amended document."
}
}
},
"auth_ref": []
},
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AmendmentFlag",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_AnnualInformationForm": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AnnualInformationForm",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Annual Information Form",
"documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_AuditedAnnualFinancialStatements": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AuditedAnnualFinancialStatements",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Audited Annual Financial Statements",
"documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CityAreaCode",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CountryRegion": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CountryRegion",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Country Region",
"documentation": "Region code of country"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_CurrentFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CurrentFiscalYearEndDate",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentAccountingStandard": {
"xbrltype": "accountingStandardItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentAccountingStandard",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Accounting Standard",
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentAnnualReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentAnnualReport",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Annual Report",
"documentation": "Boolean flag that is true only for a form used as an annual report."
}
}
},
"auth_ref": [
"r11",
"r13",
"r14"
]
},
"dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentFiscalPeriodFocus",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentFiscalYearFocus",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodStartDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentPeriodStartDate",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period Start Date",
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
}
}
},
"auth_ref": []
},
"dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentQuarterlyReport",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report."
}
}
},
"auth_ref": [
"r12"
]
},
"dei_DocumentRegistrationStatement": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentRegistrationStatement",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Registration Statement",
"documentation": "Boolean flag that is true only for a form used as a registration statement."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_DocumentShellCompanyEventDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentShellCompanyEventDate",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Event Date",
"documentation": "Date of event requiring a shell company report."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentShellCompanyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentShellCompanyReport",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Report",
"documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentTransitionReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentTransitionReport",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report."
}
}
},
"auth_ref": [
"r15"
]
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentType",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_DocumentsIncorporatedByReferenceTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentsIncorporatedByReferenceTextBlock",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Documents Incorporated by Reference [Text Block]",
"documentation": "Documents incorporated by reference."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine3": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressAddressLine3",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Three",
"documentation": "Address Line 3 such as an Office Park"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCountry": {
"xbrltype": "countryCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressCountry",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Country",
"documentation": "ISO 3166-1 alpha-2 country code."
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityBankruptcyProceedingsReportingCurrent": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityBankruptcyProceedingsReportingCurrent",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Bankruptcy Proceedings, Reporting Current",
"documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
}
}
},
"auth_ref": [
"r6"
]
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityCommonStockSharesOutstanding",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
}
}
},
"auth_ref": []
},
"dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityCurrentReportingStatus",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": []
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityExTransitionPeriod": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityExTransitionPeriod",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Elected Not To Use the Extended Transition Period",
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
}
}
},
"auth_ref": [
"r19"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityFileNumber",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityFilerCategory",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Filer Category",
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityInteractiveDataCurrent",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
}
}
},
"auth_ref": [
"r16"
]
},
"dei_EntityPrimarySicNumber": {
"xbrltype": "sicNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityPrimarySicNumber",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Primary SIC Number",
"documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_EntityPublicFloat": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityPublicFloat",
"crdr": "credit",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Public Float",
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityRegistrantName",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityShellCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityShellCompany",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntitySmallBusiness": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntitySmallBusiness",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityVoluntaryFilers": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityVoluntaryFilers",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Voluntary Filers",
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
}
}
},
"auth_ref": []
},
"dei_EntityWellKnownSeasonedIssuer": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityWellKnownSeasonedIssuer",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Well-known Seasoned Issuer",
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
}
}
},
"auth_ref": [
"r17"
]
},
"dei_Extension": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "Extension",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Extension",
"documentation": "Extension number for local phone number."
}
}
},
"auth_ref": []
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "LocalPhoneNumber",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_NoTradingSymbolFlag": {
"xbrltype": "trueItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "NoTradingSymbolFlag",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "No Trading Symbol Flag",
"documentation": "Boolean flag that is true only for a security having no trading symbol."
}
}
},
"auth_ref": []
},
"dei_OtherReportingStandardItemNumber": {
"xbrltype": "otherReportingStandardItemNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "OtherReportingStandardItemNumber",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Other Reporting Standard Item Number",
"documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r7"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r8"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "Security12bTitle",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_Security12gTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "Security12gTitle",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(g) Security",
"documentation": "Title of a 12(g) registered security."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "SecurityExchangeName",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_SecurityReportingObligation": {
"xbrltype": "securityReportingObligationItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "SecurityReportingObligation",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Reporting Obligation",
"documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
}
}
},
"auth_ref": [
"r9"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "SolicitingMaterial",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r10"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "TradingSymbol",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "WrittenCommunications",
"presentation": [
"http://veronapharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r18"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-23"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "g"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12, 13, 15d"
},
"r7": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r8": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r9": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "15",
"Subsection": "d"
},
"r10": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Section": "14a",
"Number": "240",
"Subsection": "12"
},
"r11": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-K",
"Number": "249",
"Section": "310"
},
"r12": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "240",
"Section": "308",
"Subsection": "a"
},
"r13": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Number": "249",
"Section": "220",
"Subsection": "f"
},
"r14": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Number": "249",
"Section": "240",
"Subsection": "f"
},
"r15": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Section": "13",
"Subsection": "a-1"
},
"r16": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "405"
},
"r17": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "405"
},
"r18": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
},
"r19": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "7A",
"Section": "B",
"Subsection": "2"
}
}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-24-075300-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-075300-xbrl.zip
M4$L#!!0 ( $PPVUB]$]8D9QL *>* 2 =&TR-#$X,S<P9#%?.&LN
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M[.4#(KF] +X/")H ]$;,^BC=6;/YF>!?"R9$SV9 RF^>_2905\"I:'G:'R"
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M6$![+@.JNRY\:F%U,@O:%W_WJ6U'OS\8K!CZIC&\Q5V7^A*@B7Y2>9^=P"1
M=@([VFC$1.!8U(VX$K"=1&X1:70?:7^;D/9;T[@7]O@@70'LC<]%AQV(K^U^
MEJCRT9OLUM:7]A?X*XF=7)\.'7>R=1=^YLZBU4J<=EA:S#GCG$[FJO)"+#_=
M^.0Y8-(5VO:!2#8?)DR>^3&P[\2L9OH4@")FN<<:CZ?.1H(Z>X[+0,_UF$@G
M@ZAU-MK7/]KK'YX.YX]4Y95%53Z#'A/1I5RE5MS8O%5]OWKRU!+D.:/CCDFG
M6TJ ;J/5QY,#[_TG.M[XP5Z<6"FUI"5GR3;JM5RI6JM7:O6[2 =_B0?I+Z,3
M*Q6T*,]GM95:BR6J[_X/(C8.890@5Q!%2=M1H=S4CJNC/6<$Y\25\M1_>)!X
M1.;FCR>0E(A,Y><E4XL/AXZ4/P_3J)^(9O/7@^1GEH5.]_1!DK []%T^8>(G
MD22I@L@1SR<I,U4Q!>6F/:.W_VJ2&LM2%(DBN/GGP/%8*=W\G!T??JG^$,WO
M!]5'YV-+ZTNK\'$ LHUCCV5,<P(Y_1Y2L= (\?3YB'LC<#,-@2WX\5B<\1LO
M'7W[[*!2[M[<?"D]+,N30-_&\B:&Z?;91HL*V^GW%YH9XBA;/%4U[50G7 ;4
M_>;XRIM//=AZV6\>6N%E10X>?[#-I0=+0 !GVRL526GO]!6Q0SN5'700M#P
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MHJM00C0S ;]GP S6)FEOB\XF%DL3?;XF/28RV^0A? A,IJ&JI;;S_0=%\28
M.!)D.F">#4Y"P(ETAJ$;4(_Q4+H3(B%2DOV)FFXF\![LK@,H4PZ.52I"6 =X
MUYM$S_K<!0AP'@ V<C#^EELOQ[&O,_UNIE?_>'1@CU.7I>+/A1, @3$!$GHF
M]I7IIF[SK#XX*\MW'\1F>A;Q'-U(^"/3,H:/JT[W.'<9]51#^YS13#2&IQY#
M(ZRVO=1N/A"/]?(?R[E*']/ >>+ T+\6'<&:AI2+:\;<9AKF6A:@0)II;1)
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M>H',DR:85!\;HE2&.WE<=+F# $(G1 4ZN@.GYP2D7L^7U(EG[VK! Q68'TP
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M?E[5Y(;XM@>4E*0'=+)PA(N7@JI)'O=R.)P[-D:W$-D"0'V7#H<X9))A_3X
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M(< ,OU'@1E#_,7T@P& &N;K.><3S2UGUEN;%%&CNL7-;*2A_=IG)[7>WI (
M>,19;[+E1'?E;7>_I*(N5?9W*-%7[P?#<K54JVP6[=(%&]?KN5)^$ RG3*'>
MJ ;<"VH!<S"-T+L0@"'E7],STX=<]?'01M)G/LF)RE!T=89BC=@J:DRXT_GY
M<[X2^MYZK%*Q^O";H!Y!FEN!:$%P(53.FG10H*EV<=LTH$1=&+/"ACUF8YH
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M\%:'Q$],WE*]#H#M2O%WI,V7W$QNQ1<$II+=,B*CL])@8'L0Z>,6F(=V 9!
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M P04 " !,,-M80#:6\T89 "<? %@ '1M,C0Q.#,W,&0Q7V5X.3DM
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M7"-]7=5?<XL"7Q+M!GC=>UD-X$M)<X"1N3PZ54% P1;N2S;H;MG&9#V*PG%
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M:,;PG"B1^K?)/P09OGJUT]UZ];K[>NO5=H,,BU'@*+%0R8BQ^$B3#T'Z
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M7C48[%=.ED \\/.YG9EX%C:;I>5Q^[,-[NJ=_A1DT3S.OMPGPM:-X[&SI!O
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M " !,,-M8O-T%&RX# #O"P $0 '9R;F$M,C R-# V,C8N>'-DM5;;
M<MHP$'WO3/]!]6O&-M@-:0@TDR9-2H<T*31IFI>.D 5H(DM&DKGTZROYQL5
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MU&D[NJURB/&P91B3&JV>5.8XEX "E51*EX46X1$6BNC>7K@1TM"),O3[!3?
M^)$6</]AYA3V]LU<4S#]CRFWC7XYUX:[/%WZ?74"&SI=+A1@I7'>=J.FWX(V
M1XG4%HIYLW.>;4QVU;/]JC.5P3S2?8*8G\!^0>2\ X+8<*^O\R\WP<W"M)"_
MJ],-WX>M3M=R7$R5S"T'A[#X-?F+&!*9O8)8*F>@A&LDC*AGZSKZU<WA_(F9
MO,N#F@#QF"DQVZ<1%BGYRV'5F/\'[%:(')\6P?P:'.KV@"XH.U_7 @TW5=/+
MWU!+ P04 " !,,-M8EB.O3?T* " A@ %0 '9R;F$M,C R-# V,C9?
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M#02DDOME9"DP2Q,U@/5"TI8Z/]T S+9./0Q=4)P YN!3DDKOEY3%(Z%4W0_
MK'] L8E=TP(;-GEI*X,B!K0',I-'H#(D'&PN7]3J7"Z3!C:VIO<)3\MV%S^5
M.%B$3(<#*<K#D(KS1%+M-D0/0RVE:WH JR8WABPH8NS>0%8*.<KU_B&Y9/$@
M1"J='T ,FW8\2E& <#2=]:$AU3[!N$K2"-/"RY7<EG8TSZ)U#0AHUX2D)0P*
M%,@="$L1H)G)0[P"\R^"Q3!<:DH_L+2LVE&I9 &"8GKKPT3IO4 RVPK1< W/
M.+#4V4W9'K/5_5E %P0H/>9:=VT+>0,43S/0)<N2;*^>I[O9;E9$6!K7EKAB
M S*GF3#+@V !,&4R4,B0TJ%"Z*7G]5T"EJF'&,'FF#*W!-A--BEH:@(BP6H,
MH.&@S9\I]4+$3(Y, M,YB\GN9[('V]72N64"L-F$PA %1(7=&8!%*4:Y&DFY
M%S#N1++!8K](HIZIHBUTBP9DM,F&J0H(#L :0$>I1HOYS.=,LL2[>2Q!31Z2
MXGGP'DI O5M8>FPWF0'$ :'3[1 @2 :A9I1/D.8LXN*9UQYWF/&M' #W,Q[#
M*Y2>*+=0#6I"$ZW.D( &^(3P*P1^J%X)@5Q]1Y/7@%2-7@A[B*.Y8%*RW^N
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M!(2'S5='!AF!M-8+"XL-IO3S-DT82>&)R%"Y9<%JL<E"0Q(0"S9? NY%&FM
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M&;&R"O2[J@3EM=A^O[R^Z5I^DIOU)OG7"J=$;ODO4$L#!!0 ( $PPVU@E
M:E&@6P< -U7 5 =G)N82TR,#(T,#8R-E]P<F4N>&ULS9S?<]HX$,??
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MO.A<T>EEZTD)8EOHO3I]TWOCZO]]S\BL%[9S:N;Z5BOJ[+6]4%1387*Y-_;
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M\4%]HQ 80T68+CI'NF[L ?>>VN(;]\N]B]4>^1]02P$"% ,4 " !,,-M8
MO1/6)&<; "GB@ $@ @ $ =&TR-#$X,S<P9#%?.&LN
M:'1M4$L! A0#% @ 3##;6$ VEO-&&0 G'P !8 ( !
MEQL '1M,C0Q.#,W,&0Q7V5X.3DM,2YH=&U02P$"% ,4 " !,,-M8O-T%
M&RX# #O"P $0 @ $1-0 =G)N82TR,#(T,#8R-BYX<V10
M2P$"% ,4 " !,,-M8EB.O3?T* " A@ %0 @ %N.
M=G)N82TR,#(T,#8R-E]L86(N>&UL4$L! A0#% @ 3##;6"5J4:!;!P
MW5< !4 ( !GD, '9R;F$M,C R-# V,C9?<')E+GAM;%!+
4!08 !0 % $D! L2P !
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>tm2418370d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
xmlns="http://www.xbrl.org/2003/instance"
xmlns:dei="http://xbrl.sec.gov/dei/2023"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:xlink="http://www.w3.org/1999/xlink">
<link:schemaRef xlink:href="vrna-20240626.xsd" xlink:type="simple"/>
<context id="AsOf2024-06-26">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
</entity>
<period>
<startDate>2024-06-26</startDate>
<endDate>2024-06-26</endDate>
</period>
</context>
<unit id="USD">
<measure>iso4217:USD</measure>
</unit>
<unit id="Shares">
<measure>shares</measure>
</unit>
<unit id="USDPShares">
<divide>
<unitNumerator>
<measure>iso4217:USD</measure>
</unitNumerator>
<unitDenominator>
<measure>shares</measure>
</unitDenominator>
</divide>
</unit>
<dei:AmendmentFlag contextRef="AsOf2024-06-26" id="Fact000003">false</dei:AmendmentFlag>
<dei:EntityCentralIndexKey contextRef="AsOf2024-06-26" id="Fact000004">0001657312</dei:EntityCentralIndexKey>
<dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-06-26" id="xdx2ixbrl0012">X0</dei:EntityIncorporationStateCountryCode>
<dei:EntityAddressCountry contextRef="AsOf2024-06-26" id="xdx2ixbrl0018">GB</dei:EntityAddressCountry>
<dei:DocumentType contextRef="AsOf2024-06-26" id="Fact000009">8-K</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="AsOf2024-06-26" id="Fact000010">2024-06-26</dei:DocumentPeriodEndDate>
<dei:EntityRegistrantName contextRef="AsOf2024-06-26" id="Fact000011">Verona Pharma plc</dei:EntityRegistrantName>
<dei:EntityFileNumber contextRef="AsOf2024-06-26" id="Fact000013">001-38067</dei:EntityFileNumber>
<dei:EntityTaxIdentificationNumber contextRef="AsOf2024-06-26" id="Fact000014">98-1489389</dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="AsOf2024-06-26" id="Fact000015">One Central Square</dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown contextRef="AsOf2024-06-26" id="Fact000016">Cardiff</dei:EntityAddressCityOrTown>
<dei:EntityAddressPostalZipCode contextRef="AsOf2024-06-26" id="Fact000017">CF10 1FS</dei:EntityAddressPostalZipCode>
<dei:CountryRegion contextRef="AsOf2024-06-26" id="Fact000019">44</dei:CountryRegion>
<dei:CityAreaCode contextRef="AsOf2024-06-26" id="Fact000020">203</dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="AsOf2024-06-26" id="Fact000021">283 4200</dei:LocalPhoneNumber>
<dei:WrittenCommunications contextRef="AsOf2024-06-26" id="Fact000022">false</dei:WrittenCommunications>
<dei:SolicitingMaterial contextRef="AsOf2024-06-26" id="Fact000023">false</dei:SolicitingMaterial>
<dei:PreCommencementTenderOffer contextRef="AsOf2024-06-26" id="Fact000024">false</dei:PreCommencementTenderOffer>
<dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-06-26" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
<dei:Security12bTitle contextRef="AsOf2024-06-26" id="Fact000026">Ordinary shares, nominal value £0.05 per share*</dei:Security12bTitle>
<dei:TradingSymbol contextRef="AsOf2024-06-26" id="Fact000027">VRNA</dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="AsOf2024-06-26" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
<dei:EntityEmergingGrowthCompany contextRef="AsOf2024-06-26" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>